113 related articles for article (PubMed ID: 15162426)
21. Suppression of HCV-specific T cells without differential hierarchy demonstrated ex vivo in persistent HCV infection.
Sugimoto K; Ikeda F; Stadanlick J; Nunes FA; Alter HJ; Chang KM
Hepatology; 2003 Dec; 38(6):1437-48. PubMed ID: 14647055
[TBL] [Abstract][Full Text] [Related]
22. CD8+ T lymphocyte responses are induced during acute hepatitis C virus infection but are not sustained.
Lechner F; Gruener NH; Urbani S; Uggeri J; Santantonio T; Kammer AR; Cerny A; Phillips R; Ferrari C; Pape GR; Klenerman P
Eur J Immunol; 2000 Sep; 30(9):2479-87. PubMed ID: 11009080
[TBL] [Abstract][Full Text] [Related]
23. Differential antigenic hierarchy associated with spontaneous recovery from hepatitis C virus infection: implications for vaccine design.
Smyk-Pearson S; Tester IA; Lezotte D; Sasaki AW; Lewinsohn DM; Rosen HR
J Infect Dis; 2006 Aug; 194(4):454-63. PubMed ID: 16845628
[TBL] [Abstract][Full Text] [Related]
24. CD8+ cell responses to hepatitis C virus (HCV) in the liver of persons with HCV-HIV coinfection versus HCV monoinfection.
Alatrakchi N; Graham CS; He Q; Sherman KE; Koziel MJ
J Infect Dis; 2005 Mar; 191(5):702-9. PubMed ID: 15688283
[TBL] [Abstract][Full Text] [Related]
25. Characterization of the role of CD8+T cells in breast cancer immunity following mammaglobin-A DNA vaccination using HLA-class-I tetramers.
Bharat A; Benshoff N; Fleming TP; Dietz JR; Gillanders WE; Mohanakumar T
Breast Cancer Res Treat; 2008 Aug; 110(3):453-63. PubMed ID: 17874294
[TBL] [Abstract][Full Text] [Related]
26. A liposomal peptide vaccine inducing CD8+ T cells in HLA-A2.1 transgenic mice, which recognise human cells encoding hepatitis C virus (HCV) proteins.
Engler OB; Schwendener RA; Dai WJ; Wölk B; Pichler W; Moradpour D; Brunner T; Cerny A
Vaccine; 2004 Nov; 23(1):58-68. PubMed ID: 15519708
[TBL] [Abstract][Full Text] [Related]
27. The spontaneous CD8+ T-cell response to HLA-A2-restricted NY-ESO-1b peptide in hepatocellular carcinoma patients.
Shang XY; Chen HS; Zhang HG; Pang XW; Qiao H; Peng JR; Qin LL; Fei R; Mei MH; Leng XS; Gnjatic S; Ritter G; Simpson AJ; Old LJ; Chen WF
Clin Cancer Res; 2004 Oct; 10(20):6946-55. PubMed ID: 15501973
[TBL] [Abstract][Full Text] [Related]
28. Long-term follow-up after successful interferon therapy of acute hepatitis C.
Wiegand J; Jäckel E; Cornberg M; Hinrichsen H; Dietrich M; Kroeger J; Fritsch WP; Kubitschke A; Aslan N; Tillmann HL; Manns MP; Wedemeyer H
Hepatology; 2004 Jul; 40(1):98-107. PubMed ID: 15239091
[TBL] [Abstract][Full Text] [Related]
29. Loss of IL-7 receptor alpha-chain (CD127) expression in acute HCV infection associated with viral persistence.
Golden-Mason L; Burton JR; Castelblanco N; Klarquist J; Benlloch S; Wang C; Rosen HR
Hepatology; 2006 Nov; 44(5):1098-109. PubMed ID: 17058243
[TBL] [Abstract][Full Text] [Related]
30. Polyfunctional HCV-specific T-cell responses are associated with effective control of HCV replication.
Ciuffreda D; Comte D; Cavassini M; Giostra E; Bühler L; Perruchoud M; Heim MH; Battegay M; Genné D; Mulhaupt B; Malinverni R; Oneta C; Bernasconi E; Monnat M; Cerny A; Chuard C; Borovicka J; Mentha G; Pascual M; Gonvers JJ; Pantaleo G; Dutoit V
Eur J Immunol; 2008 Oct; 38(10):2665-77. PubMed ID: 18958874
[TBL] [Abstract][Full Text] [Related]
31. Cytotoxic capacity of hepatitis C virus (HCV)--specific lymphocytes after in vitro immunization with HCV-derived lipopeptides.
Langhans B; Schweitzer S; Braunschweiger I; Schulz M; Sauerbruch T; Spengler U
Cytometry A; 2005 May; 65(1):59-68. PubMed ID: 15800857
[TBL] [Abstract][Full Text] [Related]
32. Cross-genotype-reactivity of the immunodominant HCV CD8 T-cell epitope NS3-1073.
Fytili P; Dalekos GN; Schlaphoff V; Suneetha PV; Sarrazin C; Zauner W; Zachou K; Berg T; Manns MP; Klade CS; Cornberg M; Wedemeyer H
Vaccine; 2008 Jul; 26(31):3818-26. PubMed ID: 18582999
[TBL] [Abstract][Full Text] [Related]
33. Fiber-modified recombinant adenoviral constructs encoding hepatitis C virus proteins induce potent HCV-specific T cell response.
Thammanichanond D; Moneer S; Yotnda P; Aitken C; Earnest-Silveira L; Jackson D; Hellard M; McCluskey J; Torresi J; Bharadwaj M
Clin Immunol; 2008 Sep; 128(3):329-39. PubMed ID: 18524682
[TBL] [Abstract][Full Text] [Related]
34. Functional and phenotypic characterization of peptide-vaccine-induced HCV-specific CD8+ T cells in healthy individuals and chronic hepatitis C patients.
Schlaphoff V; Klade CS; Jilma B; Jelovcan SB; Cornberg M; Tauber E; Manns MP; Wedemeyer H;
Vaccine; 2007 Sep; 25(37-38):6793-806. PubMed ID: 17686555
[TBL] [Abstract][Full Text] [Related]
35. HCV-specific T-cell responses in injecting drug users: evidence for previous exposure to HCV and a role for CD4+ T cells focussing on nonstructural proteins in viral clearance.
Ruys TA; Nanlohy NM; van den Berg CH; Hassink E; Beld M; van de Laar T; Bruisten S; Wit F; Krol A; Prins M; Lange J; van Baarle D
J Viral Hepat; 2008 Jun; 15(6):409-20. PubMed ID: 18221302
[TBL] [Abstract][Full Text] [Related]
36. Dominant influence of an HLA-B27 restricted CD8+ T cell response in mediating HCV clearance and evolution.
Neumann-Haefelin C; McKiernan S; Ward S; Viazov S; Spangenberg HC; Killinger T; Baumert TF; Nazarova N; Sheridan I; Pybus O; von Weizsäcker F; Roggendorf M; Kelleher D; Klenerman P; Blum HE; Thimme R
Hepatology; 2006 Mar; 43(3):563-72. PubMed ID: 16496339
[TBL] [Abstract][Full Text] [Related]
37. FOXP3 expression in hepatitis C virus-specific CD4+ T cells during acute hepatitis C.
Heeg MH; Ulsenheimer A; Grüner NH; Zachoval R; Jung MC; Gerlach JT; Raziorrouh B; Schraut W; Horster S; Kauke T; Spannagl M; Diepolder HM
Gastroenterology; 2009 Oct; 137(4):1280-8.e1-6. PubMed ID: 19596013
[TBL] [Abstract][Full Text] [Related]
38. Profile of tumor antigen-specific CD8 T cells in patients with hepatitis B virus-related hepatocellular carcinoma.
Gehring AJ; Ho ZZ; Tan AT; Aung MO; Lee KH; Tan KC; Lim SG; Bertoletti A
Gastroenterology; 2009 Aug; 137(2):682-90. PubMed ID: 19394336
[TBL] [Abstract][Full Text] [Related]
39. Induction of potent and long-lasting CD4 and CD8 T-cell responses against hepatitis C virus by immunization with viral antigens plus poly(I:C) and anti-CD40.
Zabaleta A; Arribillaga L; Llopiz D; Dotor J; Lasarte JJ; Prieto J; Borrás-Cuesta F; Esteban JI; Quer J; Vayreda F; Sarobe P
Antiviral Res; 2007 Apr; 74(1):25-35. PubMed ID: 17275104
[TBL] [Abstract][Full Text] [Related]
40. Dynamic programmed death 1 expression by virus-specific CD8 T cells correlates with the outcome of acute hepatitis B.
Zhang Z; Zhang JY; Wherry EJ; Jin B; Xu B; Zou ZS; Zhang SY; Li BS; Wang HF; Wu H; Lau GK; Fu YX; Wang FS
Gastroenterology; 2008 Jun; 134(7):1938-49, 1949.e1-3. PubMed ID: 18455515
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
